Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases

Patent metadata

Field	Value
Publication number	US-2023324358-A1
Application number	US-202217979453-A
Country	US
Kind code	A1
Filing date	Nov 2, 2022
Priority date	Jul 6, 2017
Publication date	Oct 12, 2023
Grant date	—

Abstract

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.

First claim

1 . An assay kit for detecting lipid peroxidation inhibitory activity of a test compound, comprising:
a compound represented by formula (I):

a cultured cell, and at least one compound selected from the group consisting of arachidonic acid and tert-butyl hydroperoxide in a buffer.

2 . The assay kit according to claim 1 , wherein the cultured cell is a human hepatoma-derived HepG2 cell.

3 . The assay kit according to claim 1 , further comprising a package insert showing an activity value of a compound having lipid peroxidation inhibitory activity.

4 . An assay kit comprising any two or more of the assay kits according to claim 1 .

5 . An assay method for measuring lipid peroxidation inhibitory activity, comprising:
i) providing the assay kit according to claim 1 ; ii) adding a test compound; iii) measuring fluorescence; and iv) determining an activity value of the test compound from the result of measuring the fluorescence.

6 . The assay method according to claim 5 , wherein providing the assay kid comprises:
preparing the buffer containing the compound represented by formula (I) and the cultured cell; and adding the at least one compound selected from the group consisting of arachidonic acid and tert-butyl hydroperoxide.

7 . The assay method according to claim 5 , further comprising
comparing the activity value of the test compound from the result of measuring the fluorescence with an activity value of a compound serving as an indicator of lipid peroxidation inhibitory activity.

8 . The assay method according to claim 5 , wherein the assay method is performed with a microwell plate.

Assignees

• Yamada Ken Ichi
• Fuso Pharmaceutical Ind

Inventors

• Yamada Ken-Ichi
• Shinto Saki
• Ide Tomomi
• Yamamoto Keiichi

Classifications

• G01N2500/00

  Screening for compounds of potential therapeutic value · CPC title

• G01N33/92 Primary

  involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} · CPC title

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• G01N33/533

  with fluorescent label · CPC title

• G01N33/52

  Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)} · CPC title